Bronstein, Gewirtz & Grossman, LLC Investigates Potential Securities Fraud Claims Against Biohaven Ltd.
NEW YORK, NY – March 12, 2025
Bronstein, Gewirtz & Grossman, LLC is currently investigating potential securities fraud claims against Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for neurological diseases. The investigation concerns whether Biohaven and certain of its officers and/or directors have violated federal securities laws.
Background
Biohaven’s lead product candidate, rimegepant, is an oral calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the preventive treatment of migraine. The company has reported positive results from several clinical trials, leading to its FDA submission for approval of rimegepant in the preventive treatment of migraine. Biohaven’s stock price has risen significantly in response to these positive trial results.
Allegations
The investigation concerns whether Biohaven and its executives may have made false and/or misleading statements and/or failed to disclose material information to the investing public. Specifically, it is alleged that the company may have downplayed the risks associated with rimegepant and overstated its potential market size and growth prospects.
Impact on Individual Investors
If the allegations are true, individual investors who purchased Biohaven securities may be able to recover their losses through a class action lawsuit. Such a lawsuit seeks to hold the company and its executives accountable for any misrepresentations or omissions made in connection with the sale of Biohaven securities.
Impact on the World
The potential impact of this investigation on the biopharmaceutical industry as a whole could be significant. If the allegations are true, it could lead to increased scrutiny of other biopharmaceutical companies and their reporting practices. It could also potentially deter investors from putting their money into the industry, which could have far-reaching consequences for research and development efforts.
Conclusion
Bronstein, Gewirtz & Grossman, LLC is dedicated to ensuring that companies adhere to ethical business practices and disclose all material information to investors. If you purchased Biohaven securities and believe that you have suffered a loss due to false or misleading statements, you may be eligible to participate in a class action lawsuit. To learn more about the investigation and your potential legal rights, please contact the firm at (212) 697-6484 or [email protected].
The information in this press release is not legal advice. The law may vary from jurisdiction to jurisdiction and the facts and circumstances described herein may or may not apply to your specific situation.
